A.P. Pharma, Inc. Licenses APF530 To RHEI Pharmaceuticals, Inc. For Development In Greater China

REDWOOD CITY, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA) and RHEI Pharmaceuticals, Inc. today announced that A.P. Pharma has granted an exclusive license to RHEI Pharmaceuticals to develop and sell APF530 in Greater China, which for the purposes of this agreement includes China, Taiwan, Hong Kong and Macau. APF530 is currently in Phase 3 trials in the U.S. for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.